本帖最后由 老马 于 2012-1-13 21:20 编辑 ) E, d+ P, M8 @! I3 y$ T
$ @" i) t% {$ k k爱必妥和阿瓦斯丁的比较
! y2 W) b, _% k( j0 \$ K
" C, x# k; ]+ w" n* a$ Zhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/7 {8 P" T: _: o1 E- x
2 U& v! z% Y* `+ D6 ], D
& A+ C' @9 n n: \8 i9 F
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
% J0 u1 Y& v! }5 q" d0 K==================================================3 b) q' }! W( b4 g
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
/ o6 G# U% w* lPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.5 `# h9 C% N4 D1 R; U+ z
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
3 q7 z/ u4 E. |" p, `
|